Moreover, although direct evidence is limited, initial studies indicate that concurrent infections or inflammatory processes in other organs (e.g., pneumonitis during PD-1/PD-L1 inhibitor therapy) can amplify systemic immune activation and potentially exacerbate the cardiotoxic effects of PD-1/PD-L1 immune checkpoint inhibitors. The gene discussed is PDCD1; the disease is infection.